Epilactose
Based on 1 Customer Validation
Epilactose is an orally active prebiotic disaccharide. Epilactose resists gastrointestinal digestion, stimulates the intestinal epithelium, and induces myosin regulatory light chain phosphorylation, activating the perijunctional actin-myosin ring and paracellular transport. Epilactose produces short-chain fatty acids and organic acids through cecal microbial fermentation, induces paracellular calcium and iron absorption, lowers cecal pH, and increases cecal calcium and magnesium solubility. Epilactose inhibits hepatic cholesterol synthesis. Epilactose can be used for research on osteopenia, colon cancer, Crohn's disease, post-gastrectomy osteopenia and anemia, and obesity.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.89%
- No. CAS: 50468-56-9
- Fòrmula: C12H22O11
- Peso molecular:342.30
-
Almacenamiento:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
In Vitro
Epilactose (1% (w/v); 68 h) supports the growth of human-derived Bifidobacterium species in vitro, with B. catenulatum JCM1194 showing the highest growth level among the tested strains (1.068 at 620 nm)[6].
Epilactose (50-100 mM; 20 min) increases paracellular Ca absorption in rat small intestinal segments in a dose-dependent manner[1].
Epilactose (50-100 mM; 20 min) induces MLC phosphorylation in rat small intestinal mucosa without affecting the association of tight junction proteins with the actin cytoskeleton[1].
The promoting effect of Epilactose (100 mM; 20 min) on Ca absorption in rat small intestinal segments is inhibited by MLCK and ROCK inhibitors, but not by PLC or tyrosine kinase inhibitors[1].
Epilactose (0-80 mM; 3 h) decreases the transepithelial electrical resistance of Caco-2 cell monolayers in a dose- and time-dependent manner at 40 and 80 mM, indicating increased paracellular transport through physiological regulation of tight junctions[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Epilactose (4.76 g/kg of BW per day; diet; ad libitum; 15 days) in healthy rats increases cecal wall and content weights, lowers cecal pH, proliferates lactobacilli and bifidobacteria, and inhibits the conversion of primary to secondary bile acids[3].
Epilactose (50 g/kg diet; p.o.; daily; 30 days) ameliorates postgastrectomy osteopenia and completely restores anemia through the promotion of intestinal Ca and Fe absorption in gastrectomized rats[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar-ST (Male, 4-week-old)[2]
-
Dosage:50 g/kg diet
-
Administration:diet; daily; 15 days
-
Result:Increased cecal wall weight to 0.38 g/100 g B.W. and cecal content weight to 2.24 g/100 g B.W.
Decreased cecal pH to 6.62.
Increased apparent calcium absorption compared to control and lactose groups.
Increased cecal calcium solubility to 32.6%.
Increased cecal magnesium solubility to 79.2%.
Decreased cecal zinc solubility to 4.9%.
Increased cecal acetate to 275 μmol, propionate to 127 μmol, n-butyrate to 46.2 μmol, total SCFAs to 447 μmol, succinate to 185 μmol, lactate to 44.9 μmol, and total organic acids to 677 μmol per whole cecal contents.
Tended to lower plasma total cholesterol and LDL+VLDL cholesterol levels.
-
Animal Model:Wistar-ST rats (male, 4 weeks old, 113.6 g)[3]
-
Dosage:4.76 g/kg of BW per day
-
Administration:diet; ad libitum; 15 days
-
Result:Achieved a body weight gain of 104.0 g over 15 days.
Recorded a total food intake of 257.7 g over 15 days.
Increased cecal wall weight to 3.8 g/kg of BW.
Increased cecal content weight to 22.9 g/kg of BW.
Lowered cecal content pH to 6.61.
Increased the number of cecal lactobacilli significantly compared to control.
Reached a logarithmic cecal bifidobacteria number of 7.80 copies/g.
Resulted in cecal α-MCA of 20.63 μmol/g of dry feces, β-MCA of 35.78 μmol/g, and total primary bile acids of 63.99 μmol/g.
Resulted in cecal deoxycholic acid of 14.67 μmol/g, lithocholic acid of 4.88 μmol/g, and total secondary bile acids of 19.55 μmol/g.
Achieved a ratio of primary to secondary bile acids of 5.41.
-
Animal Model:Sprague-Dawley (male, 4 weeks old, total gastrectomy)[5]
-
Dosage:50 g/kg diet
-
Administration:p.o.; daily; 30 days
-
Result:Increased Ca absorption rate in gastrectomized rats above that of sham rats fed the control diet.
Restored gastrectomy-impaired Fe absorption.
Reversed plasma Ca concentration to 9.22 mg/dL compared to 8.86 mg/dL in control diet.
Partially recovered plasma Fe concentration to 26.2 mg/dL compared to 17.5 mg/dL in control diet.
Increased femoral dry weight to 203 mg/rat compared to 168 mg/rat in control diet.
Increased femoral Ca content to 53.6 mg/whole femur compared to 40.8 mg/whole femur in control diet.
Increased bone strength compared to control diet.
Increased hematocrit and hemoglobin concentration on day 15 compared to control diet.
Recovered hematocrit and hemoglobin to levels comparable to sham rats on day 30.
Increased cecal tissue and content weights compared to control group.
Decreased pH of cecal contents compared to control group.
Increased soluble Ca concentration in cecal contents compared to control diet.
Increased soluble Fe concentration in cecal contents compared to control diet.
Increased acetic acid pool to 365 μmol/whole cecal content, propionic acid pool to 136 μmol/whole cecal content, butyric acid pool to 60.0 μmol/whole cecal content, and total SCFA pool to 562 μmol/whole cecal content compared to sham rats fed the epilactose diet.
Chemical Information
-
No. CAS 50468-56-9
-
Appearance Solid
-
Peso molecular 342.30
-
Fòrmula C12H22O11
-
Color White to light yellow
-
SMILES
O=C[C@@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)O)O)CO
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Pureza y Documentación
-
Ficha de datos (295 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Epilactose Related Classifications
HY-N10618 Related Classifications
Powered by Bioz
Keywords
- Epilactose
- 50468-56-9
- Biochemical Assay Reagents
- short-chain fatty acids
- MLCK/ROCK inducer
- bifidobacteria
- Caco-2 cell monolayers
- myosin regulatory light chain phosphorylation
- lactobacilli
- cecal microbial fermentation
- paracellular calcium and iron absorption
- Crohn's disease
- postgastrectomy osteopenia
- Inhibitor
- inhibitor
- inhibit